Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

SRR12696790

—

354e724a-94b4-52cc-aaab-54b719f1d929

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V1+0.400
  • PANCREAS_BETA_CELLS+0.400
  • OXIDATIVE_PHOSPHORYLATION+0.300
  • ADIPOGENESIS+0.200
  • ANGIOGENESIS+0.200
  • BILE_ACID_METABOLISM+0.200
  • COAGULATION+0.200
  • GLYCOLYSIS+0.200
  • INTERFERON_ALPHA_RESPONSE+0.200
  • KRAS_SIGNALING_DN+0.200

Top 10 suppressed

  • WNT_BETA_CATENIN_SIGNALING-0.400
  • TNFA_SIGNALING_VIA_NFKB-0.300
  • KRAS_SIGNALING_UP-0.200
  • MITOTIC_SPINDLE-0.200
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.200
  • TGF_BETA_SIGNALING-0.200
  • UV_RESPONSE_DN-0.200
  • CHOLESTEROL_HOMEOSTASIS-0.100
  • E2F_TARGETS-0.100
  • ESTROGEN_RESPONSE_LATE-0.100

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1C3N-01415
lung-landscapes@6
—cohortA10.691
2SRR1313114
breast-umap@18
—B0.629
3MNG785
mng-umap@100
——0.609
4SRR10899988
melanoma-umap@29
——0.599
5TCGA-A8-A08J-01A-11R-A00Z-07
breast-umap@18
—B0.596
6BS_JTMXAMB7
medullo-epn-umap@date-based
MedMedulloblastoma0.593
7131a9973-dfc9-4897-8c19-d5c43cecba0a
colon-landscapes@1
——0.583
8TCGA-E9-A22B-01A-11R-A157-07
breast-umap@18
—C0.565
9SRR12696791
melanoma-umap@29
——0.561
10ULC1633T_S98
lung-landscapes@6
—cohortA10.553

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V10.400Inavolisib— uncovered
PANCREAS_BETA_CELLS0.400Cobimetinib— uncovered
OXIDATIVE_PHOSPHORYLATION0.300Remibrutinib— uncovered
ADIPOGENESIS0.200Inavolisib— uncovered
ANGIOGENESIS0.200Remibrutinib— uncovered
BILE_ACID_METABOLISM0.200Inavolisib— uncovered
COAGULATION0.200Binimetinib— uncovered
GLYCOLYSIS0.200Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.200Inavolisib— uncovered
KRAS_SIGNALING_DN0.200Remibrutinib— uncovered
MTORC1_SIGNALING0.200Inavolisib— uncovered
PEROXISOME0.200Idelalisib— uncovered
PROTEIN_SECRETION0.200Remibrutinib— uncovered
APICAL_JUNCTION0.100Inavolisib— uncovered
APICAL_SURFACE0.100Temsirolimus— uncovered
COMPLEMENT0.100Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.100Inavolisib— uncovered
FATTY_ACID_METABOLISM0.100Inavolisib— uncovered
HEDGEHOG_SIGNALING0.100Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.100Idelalisib— uncovered